ADBIOTECH CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,180 KRW | +11.58% |
|
+21.61% | -2.90% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Capitalization 1 | 37,494 | 45,092 | 30,712 | 29,935 |
| Enterprise Value (EV) 1 | 41,890 | 55,480 | 34,855 | 34,131 |
| P/E ratio | -5.15 x | -26.2 x | 28.3 x | -10.5 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 3.82 x | 3.81 x | 2.89 x | 2.86 x |
| EV / Revenue | 4.27 x | 4.69 x | 3.28 x | 3.26 x |
| EV / EBITDA | -51.4 x | -61.4 x | -8.19 x | -9.38 x |
| EV / FCF | - | -11,182,540 x | -10,732,842 x | -27,117,975 x |
| FCF Yield | - | -0% | -0% | -0% |
| Price to Book | 4.05 x | 13.7 x | 1.9 x | 2.24 x |
| Nbr of stocks (in thousands) | 4,955 | 4,955 | 9,140 | 9,140 |
| Reference price 2 | 7,567 | 9,100 | 3,360 | 3,275 |
| Announcement Date | 3/16/22 | 3/16/22 | 3/22/23 | 3/20/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net sales 1 | 9,815 | 11,840 | 10,632 | 10,472 |
| EBITDA 1 | -815.1 | -903 | -4,258 | -3,639 |
| EBIT 1 | -996.2 | -1,555 | -4,984 | -4,772 |
| Operating Margin | -10.15% | -13.13% | -46.88% | -45.57% |
| Earnings before Tax (EBT) 1 | -7,476 | -2,415 | 2,696 | -5,457 |
| Net income 1 | -7,345 | -2,664 | 2,696 | -2,863 |
| Net margin | -74.83% | -22.5% | 25.36% | -27.34% |
| EPS 2 | -1,470 | -347.0 | 118.5 | -313.3 |
| Free Cash Flow | - | -4,961 | -3,247 | -1,259 |
| FCF margin | - | -41.9% | -30.55% | -12.02% |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 3/16/22 | 3/16/22 | 3/22/23 | 3/20/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net Debt 1 | 4,396 | 10,388 | 4,143 | 4,196 |
| Net Cash position 1 | - | - | - | - |
| Leverage (Debt/EBITDA) | -5.393 x | -11.5 x | -0.973 x | -1.153 x |
| Free Cash Flow | - | -4,961 | -3,247 | -1,259 |
| ROE (net income / shareholders' equity) | - | -36.9% | 25.3% | -37.8% |
| ROA (Net income/ Total Assets) | - | -4.88% | -12% | -10.1% |
| Assets 1 | - | 54,571 | -22,497 | 28,374 |
| Book Value Per Share 2 | 1,866 | 664.0 | 1,771 | 1,465 |
| Cash Flow per Share 2 | 488.0 | 155.0 | 129.0 | 330.0 |
| Capex 1 | 5,289 | 3,561 | 727 | 240 |
| Capex / Sales | 53.89% | 30.08% | 6.84% | 2.29% |
| Announcement Date | 3/16/22 | 3/16/22 | 3/22/23 | 3/20/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -2.90% | 21.28M | |
| -12.83% | 78.51B | |
| +25.12% | 3.71B | |
| -0.42% | 3.27B | |
| -1.21% | 1.64B | |
| +15.20% | 1.64B | |
| -18.97% | 1.36B | |
| +1.56% | 1.34B | |
| -6.82% | 1.22B | |
| +4.02% | 1.12B |
- Stock Market
- Equities
- A179530 Stock
- Financials ADBiotech Co., Ltd.
